Gruppo Oncologico del Nord-Ovest
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 1987-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://gonogroup.org/
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 238
- Registration Number
- NCT06733038
- Locations
- 🇮🇹
Istituto Oncologico Veneto Irccs, Padova, PD, Italy
🇮🇹Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy
🇮🇹U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 16
- Registration Number
- NCT06578559
- Locations
- 🇮🇹
Pia Fondazione di Culto e di Religione Cardinale G. Panico, Tricase, LE, Italy
🇮🇹Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst, Meldola, FC, Italy
🇮🇹Fondazione Casa Sollievo Della Sofferenza - Irccs, San Giovanni Rotondo, FG, Italy
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06253650
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 300
- Registration Number
- NCT06037980
- Locations
- 🇮🇹
Humanitas Cancer Center, Milan, Italy
🇮🇹Azienda Ospedaliera Universitaria Pisa, Pisa, Italy
🇮🇹ASST Spedali Civili, Brescia, Italy
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
- Conditions
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 124
- Registration Number
- NCT05802290
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Ospedale Bellaria, Bologna, Italy
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 36
- Registration Number
- NCT05594290
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 63
- Registration Number
- NCT05253846
- Locations
- 🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- Conditions
- Interventions
- Drug: 5-Fluorouracil continuous infusion FOLFOXIRI scheduleDrug: 5-Fluorouracil bolus FOLFOX scheduleDrug: Trifluridine/TipiracilDrug: Oxaliplatin FOLFOX and FOLFOXIRI scheduleDrug: 5-Fluorouracil continuous infusion FOLFOX scheduleDrug: L-LeucovorinDrug: Oxaliplatin CAPOX scheduleDrug: IrinotecanDrug: CapecitabineDrug: TrastuzumabDrug: Tucatinib
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 477
- Registration Number
- NCT05062889
- Locations
- 🇮🇹
Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy
🇮🇹Ospedale San Donato di Arezzo, Arezzo, Italy